Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 29 clinical trials
Featured trial
TOL2506A: A Phase 3, Single Arm, Open-Label Study Evaluating Ovarian Suppression Following Three-Month Leuprolide Acetate For Injectable Suspension (TOL2506) in Combination with Endocrine Therapy in Premenopausal Subjects with Hormone-Receptor–Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer

those who will initiate therapy with an AI (letrozole, anastrozole, or exemestane) beginning 6 weeks after the first administration of TOL2506, upon confirmation that estradiol (E2) levels of < 20 pg

endocrine therapy
estradiol
letrozole
hormone therapy
her2/neu-negative breast cancer
  • 0 views
  • 07 Jan, 2022
  • 1 location
Exemestane Letrozole or Anastrozole in Treating Postmenopausal Women With Clinical Stage II and III Estrogen Receptor Positive Breast Cancer

are exemestane, anastrozole, letrozole. The purpose of this study is to find out whether it is better to receive exemestane, anastrozole, or letrozole to improve the chance that the

anastrozole
letrozole
estrogen receptor
hormone therapy
estrogen
  • 33 views
  • 07 Nov, 2020
  • 1 location
A Study of Lerociclib in Participants With Advanced Breast Cancer

first line endocrine therapy such as tamoxifen, anastrozole, or letrozole (2L population). All premenopausal or perimenopausal female participants, and all male participants, must be receiving goserelin

  • 0 views
  • 09 Apr, 2022
  • 3 locations
Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients (HERMIONE-7) (HERMIONE-7)

The HERMIONE-7 trial is a phase II, single-arm, open-label, multicenter study in HR+, HER2- advanced breast cancer patients who have received HD-FUL as first-line endocrine treatment for their metastatic disease. Patients will receive aromatase inhibitors plus Abemaciclib.

HER2
abemaciclib
measurable disease
progesterone
aromatase inhibitor
  • 39 views
  • 25 Mar, 2022
  • 38 locations
Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6) (SERENA-6)

The study is intended to show superiority of AZD9833 in combination with CDK4/6 inhibitor (palbociclib or abemaciclib) versus aromatase inhibitors (anastrozole or letrozole) in combination with

  • 22 views
  • 12 May, 2022
  • 119 locations
A Comparative Study of AZD9833 Plus Palbociclib Versus Anastrozole Plus Palbociclib in Patients With ER-Positive HER2 Negative Breast Cancer Who Have Not Received Any Systemic Treatment for Advanced Disease. (SERENA-4)

The study is intended to show superiority of AZD9833 in combination with palbociclib (a CDK4/6 inhibitor) versus anastrozole (an aromatase inhibitor) and palbociclib as the initial treatment of

  • 0 views
  • 06 May, 2022
  • 182 locations
Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer (POLAR)

modulator (such as tamoxifen) or an aromatase inhibitor (anastrozole, letrozole, exemestane) or fulvestrant (Faslodex). Premenopausal women and men may also receive a drug called an LHRH (luteinizing

endocrine therapy
letrozole
estrogen receptor
cancer
gnrh
  • 2 views
  • 19 Feb, 2022
  • 55 locations
SHR6390 Combined With Anastrozole for Preoperative Treatment of Breast Cancer.

The study is being conducted to assess effect of SHR6390 combined with anastrozole on proliferation of HR-positive HER2-negative breast cancer tumor cells before surgery.

anastrozole
HER2
tumor cells
her2/neu-negative breast cancer
erbb2
  • 0 views
  • 25 Apr, 2022
  • 1 location
Anastrozole Palbociclib Trastuzumab and Pertuzumab in HR-positive HER2-positive Metastatic Breast

This is a multicenter, phase I/II trial of anastrozole, palbociclib, trastuzumab, and pertuzumab is proposed as first-line therapy in metastatic hormone receptor-positive, HER2-positive breast

stage iv breast cancer
HER2
tumor cells
core needle biopsy
cancer
  • 38 views
  • 09 Jul, 2021
  • 7 locations
Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer

This phase II trial studies how well anastrozole and letrozole after surgery work in treating patients with stage I-III breast cancer. Drugs, such as anastrozole and letrozole, may stop the

tumor cells
estrogen receptor
cancer
carcinoma
adjuvant chemotherapy
  • 0 views
  • 24 Mar, 2022
  • 3 locations